Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Prometheus Biosciences (RXDX) to $114 from $67 and keeps an Overweight rating on the shares. The stock in late morning trading is up 169% to $97.02. The analyst views the PRA023 data as "stellar" and believes Prometheus is well positioned to conduct the Phase 3 design. Today’s data establishes PRA023’s high efficacy in ulcerative colitis and Crohn’s disease as a whole in the "all-comer population and offers a unique opportunity for a precision medicine approach with TL1A, which ultimately supports further pipeline expansion into other inflammatory diseases," Rahimi tells investors in a research note. She believes Prometheus’s current evaluation is a good comp in inflammatory bowel disease to Arena Pharmaceuticals with etrasimod that was acquired by Pfizer (PFE) for $6.7B.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RXDX:
- Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
- Prometheus Biosciences Shares Tripled Today after Positive Drug Results
- Prometheus shares should be up ‘meaningfully’ after UC/CD data, says Wells Fargo
- Prometheus’ PRA023 phase 2b trial data exceed expectations, says RBC Capital
- Prometheus announces results for PRA023 in APOLLO-CD Phase 2 study